News and Announcements
Antisense Therapeutics Limited releases update on Growth Hormone Receptor
- Published May 18, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Antisense Therapeutics Limited (ASX:ANP) provides the following update on ATL1103, an antisense drug targeting the Growth Hormone receptor (GHr), in clinical development for acromegaly.
KEY TAKEAWAYS:
- ATL1103 Phase II clinical trial data submitted for publication in high-quality scientific journal
- Partnering interactions progressing